Safety of long-acting β-agonists in asthma

Thorax

Volumn 67, Issue 11, 2012, Pages 1015-

  Rodrigo, Gustavo J ^a   Castro Rodriguez, Jose A ^b  

^a HOSPITAL CENTRAL DE LAS FUERZAS ARMADAS   (Uruguay)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; LONG ACTING DRUG; PLACEBO;

ASTHMA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84868206077     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202014     Document Type: Letter

References (3)

1. Wolfe J, Laforce C, Friedman B, et al. Formoterol, 24 μg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 μg bid, with and without extra doses taken on demand, and placebo. Chest 2006;129:27-38. (Pubitemid 43265240)
2. Rodrigo GJ, Castro-Rodriguez JA. Safety of long-acting β agonists for the treatment of asthma: clearing the air. Thorax 2012;67:342-9.
3. Mann M, Chowdhury B, SulliVan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003;124:70-4. (Pubitemid 36851333)